The Electrospinning Company offers contract services to design, develop and manufacture nanofibrous biomaterials for medical devices. Based on the electrospinning platform technology, they use their expertise and experience to support clients in a range of different therapeutic indications, including the supply of the first electrospun biomaterial incorporated into an FDA-approved medical device. The Company is also developing proprietary materials for targeted out-licensing opportunities, aiming to capture more of the end-market value. They are a spin-out from the UK Science and Technology Facilities Council (STFC) and are located on the Harwell Innovation Campus near Oxford, UK. Further information can be found on the company’s website.